PP2

PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.

Product Specifications

CAS Number

[172889-27-9]

Product Name Alternative

AGL 1879

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Src

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PP2.html

Purity

98.34

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

NC1=C2C(N(C(C)(C)C)N=C2C3=CC=C(Cl)C=C3)=NC=N1

Molecular Formula

C15H16ClN5

Molecular Weight

301.77

Precautions

H302, H315, H319, H335

References & Citations

[1]Hanke JH, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependentT cell activation. J Biol Chem. 1996 Jan 12;271 (2) :695-701.|[2]Duxbury MS, et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired Gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10 (7) :2307-18|[3]Summy JM, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther. 2005 D|[4]Inoue A, et al. Phosphorylation of NMDA receptor GluN2B subunit at Tyr1472 is important for trigeminal processing of itch. Eur J Neurosci. 2016 Oct;44 (7) :2474-2482.